Clearside Biomedical’s (CLSD) “Buy” Rating Reaffirmed at HC Wainwright

Clearside Biomedical (NASDAQ:CLSD)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 331.03% from the company’s current price.

CLSD has been the topic of a number of other research reports. Oppenheimer assumed coverage on shares of Clearside Biomedical in a report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 price target on the stock. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.60.

Clearside Biomedical Trading Down 0.9 %

Shares of NASDAQ:CLSD traded down $0.01 during trading on Tuesday, reaching $1.16. The company had a trading volume of 521,708 shares, compared to its average volume of 266,556. The company has a fifty day moving average of $1.24 and a two-hundred day moving average of $1.33. The stock has a market capitalization of $86.69 million, a P/E ratio of -2.11 and a beta of 2.43. Clearside Biomedical has a 12 month low of $0.65 and a 12 month high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.98 million. During the same quarter last year, the firm earned ($0.15) earnings per share. As a group, equities research analysts predict that Clearside Biomedical will post -0.63 earnings per share for the current year.

Institutional Investors Weigh In On Clearside Biomedical

Several institutional investors and hedge funds have recently modified their holdings of CLSD. International Assets Investment Management LLC bought a new stake in shares of Clearside Biomedical in the first quarter worth approximately $57,000. Rosalind Advisors Inc. bought a new stake in Clearside Biomedical during the first quarter valued at approximately $3,967,000. SG Americas Securities LLC bought a new stake in Clearside Biomedical during the first quarter valued at approximately $49,000. Vanguard Group Inc. grew its position in Clearside Biomedical by 14.5% during the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after buying an additional 314,480 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in Clearside Biomedical during the second quarter valued at approximately $368,000. 18.75% of the stock is owned by hedge funds and other institutional investors.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.